0001567619-23-001396.txt : 20230127 0001567619-23-001396.hdr.sgml : 20230127 20230127213500 ACCESSION NUMBER: 0001567619-23-001396 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230125 FILED AS OF DATE: 20230127 DATE AS OF CHANGE: 20230127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ajer Jeffrey Robert CENTRAL INDEX KEY: 0001557533 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 23565028 MAIL ADDRESS: STREET 1: C/O BIOMARIN PHARMACEUTICAL INC. STREET 2: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 4 1 doc1.xml FORM 4 X0306 4 2023-01-25 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001557533 Ajer Jeffrey Robert C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2023-01-25 4 M 0 49000 67.81 A 90088 D Common Stock 2023-01-25 4 S 0 44825 115.654 D 45263 D Common Stock 2023-01-25 4 S 0 4175 116.1540 D 41088 D Stock Option (Right to buy Common Stock) 67.81 2023-01-25 4 M 0 2200 0 D 2013-11-15 2023-05-14 Common Stock 2200 0 D Stock Option (Right to buy Common Stock) 67.81 2023-01-25 4 M 0 46800 0 D 2013-11-15 2023-05-14 Common Stock 46800 0 D Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. The price in column 4 is the weighted average price. The price actually received ranged from $115.000 to 115.998. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. The price in column 4 is the weighted average price. The price actually received ranged from $116.000 to $116.485. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Reflects the number of options outstanding after the transactions from this specific stock option grant. /s/ Eric Fleekop, Attorney-in-Fact 2023-01-27